Keith M O Wilson
Overview
Explore the profile of Keith M O Wilson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charles K, Wilson K, Roberts D
Transfus Med
. 2024 Oct;
35(1):24-32.
PMID: 39374942
To compare the historical development of blood transfusion in Britain and a former British West Indian colony. International transfusion bodies recommend national coordination and exclusively voluntary non-remunerated donation as essential...
2.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson K, et al.
Bone Marrow Transplant
. 2024 May;
59(8):1205.
PMID: 38740952
No abstract available.
3.
Robin M, Iacobelli S, Koster L, Passweg J, Avenoso D, Wilson K, et al.
Bone Marrow Transplant
. 2024 Mar;
59(7):928-935.
PMID: 38491198
We aimed to compare outcomes following treosulfan (TREO) or busulfan (BU) conditioning in a large cohort of myelofibrosis (MF) patients from the EBMT registry. A total of 530 patients were...
4.
Drozd-Sokolowska J, Gras L, Koster L, Martino R, Salas M, Salmenniemi U, et al.
Haematologica
. 2024 Jan;
109(5):1608-1613.
PMID: 38205539
No abstract available.
5.
Nabergoj M, Eikema D, Koster L, Platzbecker U, Sockel K, Finke J, et al.
Bone Marrow Transplant
. 2024 Jan;
59(3):395-402.
PMID: 38195984
Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this...
6.
Duque-Afonso J, Finke J, Ngoya M, Galimard J, Craddock C, Raj K, et al.
Bone Marrow Transplant
. 2023 Dec;
59(2):247-254.
PMID: 38040842
Conditioning protocols for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) are being developed continuously to improve their anti-leukemic efficacy and reduce their toxicity. In this study, we compared the conditioning...
7.
Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al.
Bone Marrow Transplant
. 2023 Nov;
59(2):217-223.
PMID: 37978322
The intensity of the conditioning regimen given before allogeneic hematopoietic cell transplantation (allo-HCT) can vary substantially. To confirm the ability of the recently developed transplant conditioning intensity (TCI) score to...
8.
Tilmont R, Yakoub-Agha I, Eikema D, Zinger N, Haenel M, Schaap N, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1182-1188.
PMID: 37543712
In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning...
9.
Maffini E, Labopin M, Beelen D, Kroeger N, Arat M, Wilson K, et al.
Bone Marrow Transplant
. 2022 Jul;
57(10):1556-1563.
PMID: 35835997
Measurable residual disease (MRD) assessment before allogeneic hematopoietic cell transplantation (HCT) may help physicians to identify a subgroup of patients at high risk of relapse for de novo acute myeloid...
10.
Lawless S, Iacobelli S, Knelange N, Chevallier P, Blaise D, Milpied N, et al.
Haematologica
. 2022 Jun;
108(4):1105-1114.
PMID: 35770529
Primary plasma cell leukemia (pPCL) is a rare and challenging malignancy. There are limited data regarding optimum transplant approaches. We therefore undertook a retrospective analysis from 1998-2014 of 751 patients...